BR112014025251B1 - uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo - Google Patents

uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo Download PDF

Info

Publication number
BR112014025251B1
BR112014025251B1 BR112014025251-3A BR112014025251A BR112014025251B1 BR 112014025251 B1 BR112014025251 B1 BR 112014025251B1 BR 112014025251 A BR112014025251 A BR 112014025251A BR 112014025251 B1 BR112014025251 B1 BR 112014025251B1
Authority
BR
Brazil
Prior art keywords
xii
pyrazin
alkyl
imidazo
muscle
Prior art date
Application number
BR112014025251-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Fady Malik
Jeffrey R. Jasper
Adam Kennedy
Darren Hwee
Original Assignee
Fady Malik
Jeffrey R. Jasper
Adam Kennedy
Darren Hwee
Cytokinetics, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fady Malik, Jeffrey R. Jasper, Adam Kennedy, Darren Hwee, Cytokinetics, Inc filed Critical Fady Malik
Publication of BR112014025251B1 publication Critical patent/BR112014025251B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014025251-3A 2012-04-11 2013-04-11 uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo BR112014025251B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261623003P 2012-04-11 2012-04-11
US61/623,003 2012-04-11
US201261646842P 2012-05-14 2012-05-14
US61/646,842 2012-05-14
US201261693061P 2012-08-24 2012-08-24
US61/693,061 2012-08-24
US201261735809P 2012-12-11 2012-12-11
US61/735,809 2012-12-11
PCT/US2013/036114 WO2013155262A2 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Publications (1)

Publication Number Publication Date
BR112014025251B1 true BR112014025251B1 (pt) 2021-03-02

Family

ID=49328282

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025251-3A BR112014025251B1 (pt) 2012-04-11 2013-04-11 uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo

Country Status (15)

Country Link
US (2) US20150250784A1 (https=)
EP (1) EP2836590A4 (https=)
JP (2) JP6352244B2 (https=)
KR (1) KR102163931B1 (https=)
CN (2) CN111840294A (https=)
AU (3) AU2013245917A1 (https=)
BR (1) BR112014025251B1 (https=)
CA (1) CA2869675C (https=)
EA (1) EA032480B1 (https=)
HK (1) HK1206389A1 (https=)
IL (2) IL234886A (https=)
MX (1) MX2014012179A (https=)
PH (1) PH12014502286B1 (https=)
SG (2) SG11201406359TA (https=)
WO (1) WO2013155262A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
HUE057533T2 (hu) * 2014-04-29 2022-05-28 Cytokinetics Inc Eljárások vitálkapacitás csökkenésének gátlására
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
JP6573618B2 (ja) * 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
BR112018016475A2 (en) 2016-02-12 2018-12-26 Cytokinetics, Incorporated tetrahydroisoquinoline derivatives
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
KR20220038056A (ko) 2019-07-23 2022-03-25 아모피컬 리미티드 운동 수행능력을 개선시키기 위한 비정질 탄산칼슘
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
WO2022099011A1 (en) 2020-11-06 2022-05-12 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139081A (ja) * 2003-11-04 2005-06-02 Takada Seiyaku Kk ビントペロール含有製剤
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CN101522681B (zh) * 2006-08-02 2012-10-03 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
SG10201701101YA (en) * 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function

Also Published As

Publication number Publication date
HK1206389A1 (en) 2016-01-08
PH12014502286A1 (en) 2014-12-15
JP6535727B2 (ja) 2019-06-26
JP2015516392A (ja) 2015-06-11
CA2869675C (en) 2022-06-14
JP6352244B2 (ja) 2018-07-04
MX2014012179A (es) 2015-07-14
AU2013245917A1 (en) 2014-10-23
US20190167676A1 (en) 2019-06-06
IL250473A0 (en) 2017-03-30
PH12014502286B1 (en) 2014-12-15
CA2869675A1 (en) 2013-10-17
AU2018200930A1 (en) 2018-03-01
KR102163931B1 (ko) 2020-10-12
CN104395458A (zh) 2015-03-04
KR20160046694A (ko) 2016-04-29
SG11201406359TA (en) 2014-11-27
WO2013155262A3 (en) 2013-12-27
US20150250784A1 (en) 2015-09-10
SG10201704166RA (en) 2017-06-29
AU2019268177A1 (en) 2019-12-12
EP2836590A4 (en) 2016-04-13
EA032480B1 (ru) 2019-06-28
EP2836590A2 (en) 2015-02-18
WO2013155262A2 (en) 2013-10-17
IL234886A (en) 2017-02-28
CN111840294A (zh) 2020-10-30
EA201491666A1 (ru) 2015-03-31
JP2018048209A (ja) 2018-03-29

Similar Documents

Publication Publication Date Title
JP6535727B2 (ja) 骨格筋疲労に対する耐性を向上させるための方法
AU2017272286B2 (en) Methods for improving diaphragm function
ES2723876T3 (es) Nuevos derivados de pirazol
BR112021008905A2 (pt) compostos de piridazinona e usos dos mesmos
KR20090098884A (ko) 약제학적 조성물 및 이의 사용방법
CN107108671A (zh) 作为raf激酶抑制剂的化合物和组合物
TW200808812A (en) Imidazo compounds
BR112020026062A2 (pt) derivados de benzodiazepina, composições, e métodos para o tratamento de comprometimento cognitivo
KR20200139702A (ko) 칼페인 조정자 및 그 치료학적 용도
JP2016528266A (ja) 位相変位睡眠障害を処置するためのＶ１ａアンタゴニスト
KR20130129906A (ko) 시그마 수용체-매개 장애를 치료하기 위한 시클릭 아미드 유도체의 사용 방법
KR20200090198A (ko) 트로포미오신 수용체 키나제 A(TrkA) 저해제로서의 피리미딘 유도체
PT1853241E (pt) Utilização de 2-(2-nitro-4-trifluorometilbenzoil)-1,3- ciclohexanodiona no tratamento de doença de parkinson
EA041725B1 (ru) Применение активатора тропонина скелетных мышц
HK1261324A1 (en) Methods for improving diaphragm function
BR112016014564B1 (pt) Compostos derivados de benzodiazepina, composição farmacêutica compreendendo ditos compostos e uso da mesma para o tratamento de deficiência cognitiva associada a um distúrbio do sistema nervoso central

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.